Australian biotech co buys into foetal cell recovery
This article was originally published in Clinica
Executive Summary
Australian public company Genetic Technologies is investing $2.65 million in Fort Collins, Colorado-based Cytomation, a company whose work on foetal cell recovery research first drew it to the Australian company's notice. It already held a very small (0.5%) of the equity in Cytomation since February, but three further investments have now brought its total holdings to 10% approximately.